Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 1, 2017, Pages 244-252

  Rao, Hui Ying ^a   Li, Hong ^b   Chen, Hong ^c   Shang, Jia ^d   Xie, Qing ^e   Gao, Zhi Liang ^f   Li, Jun ^g   Sun, Yongtao ^h   Jiang, Jianning ⁱ   Wang, Lei ^j   Zhao, Longfeng ^k   Zhang, Lunli ^l   Yang, Weibo ^m   Niu, Junqi ⁿ   Gong, Zuojiong ^o   Gong, Guozhong ^p   Yang, Ruifeng ^a   Lee, Mei Hsuan ^q   Wei, Lai ^a  

^a PEKING UNIVERSITY   (China)

^b BRISTOL MYERS SQUIBB   (United States)

^c LANZHOU UNIVERSITY   (China)

^d HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^g THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^h FOURTH MILITARY MEDICAL UNIVERSITY   (China)

ⁱ FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^j THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^k SHANXI MEDICAL UNIVERSITY   (China)

^l NANCHANG UNIVERSITY   (China)

^m KUNMING MEDICAL UNIVERSITY   (China)

ⁿ THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^o RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^p CENTRAL SOUTH UNIVERSITY   (China)

^q NATIONAL YANG MING UNIVERSITY   (Taiwan)

more..

Author keywords

cirrhosis; genotype 1b; HCV; SVR; treatment pattern

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; BIOLOGICAL MARKER; INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; CHINA; CHRONIC HEPATITIS C; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GROUPS BY AGE; HAN CHINESE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MONOTHERAPY; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; THYROID DISEASE; TREATMENT DURATION; AGED; BLOOD; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; BIOMARKERS; CHINA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008476600     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13467     Document Type: Article

References (28)

1. Mohd Hanafiah K, Groeger J, Flaxman AD et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–42.
2. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland. Accessed 15 April 2015.
3. Sievert W, Altraif I, Razavi HA et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 (Suppl 2): 61–80.
4. Duan Z, Jia JD, Hou J et al. Current challenges and the management of chronic hepatitis C in mainland China. J. Clin. Gastroenterol. 2014; 48: 679–86.
5. Rao H, Wei L, Lopez-Talavera JC et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J. Gastroenterol. Hepatol. 2014; 29: 545–53.
6. Pawlotsky JM, Feld JJ, Zeuzem S et al. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 2015; 62: S87–99.
7. Unknown. Guideline for prevention and treatment of hepatitis C-2015 update. The 17th National Liver Disease and Infectious Disease Congress. 2015.
8. Chen YD, Liu MY, Yu WL et al. Hepatitis C virus infections and genotypes in china. Hepatobiliary Pancreat. Dis. Int. 2002; 1: 194–201.
9. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int. J. Cancer 2014; 135: 1119–26.
10. Bennett H, Waser N, Johnston K et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol. Int. 2015; 9: 378–90.
11. Ghany MG, Strader DB, Thomas DL et al. American association for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–74.
12. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
13. Guo X, Zhao Z, Xie J et al. Prediction of response to pegylated-interferon-alpha and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol. J. 2012; 9: 123–422X-9-123.
14. He LL, Chen Z, Chen Y et al. Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients. Zhonghua Gan Zang Bing Za Zhi 2011; 19: 34–7.
15. Liao XW, Ling Y, Li XH et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir. Ther. 2011; 16: 141–7.
16. Ma LN, Chen XY, Chen J et al. Efficacy, influencing factors and safety of PEG-INF alpha-2a (PEG-INF-2a) in the treatment of chronic hepatitis C: analysis of 89 patients. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2006; 20: 42–5.
17. Tsang OT, Zee JS, Chan JM et al. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J. Gastroenterol. Hepatol. 2010; 25: 766–71.
18. Yu JW, Wang GQ, Sun LJ et al. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J. Gastroenterol. Hepatol. 2007; 22: 832–6.
19. Zhou BT, Fan YM, Li TM et al. Effectiveness of combined therapies using two types of peginterferon and ribavirin in treating chronic hepatitis C virus genotypes 1b/6a infections. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2010; 32: 320–3.
20. Lee MH, Lu SN, Yuan Y et al. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014; 9: e94760. DOI: 10.1371/journal.pone.0094760;.
21. Lee MH, Yang HI, Lu SN et al. A liver cirrhosis risk calculator for patients infected with hepatitis C virus. APASL 2015; 2015; P1218.
22. Bruno S, Crosignani A, Maisonneuve P et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350–6.
23. Raimondi S, Bruno S, Mondelli MU et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 2009; 50: 1142–54.
24. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 2010; 28: 4587–93.
25. Moorman AC, Gordon SC, Rupp LB et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin. Infect. Dis. 2013; 56: 40–50.
26. Ly KN, Xing J, Klevens RM et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012; 156: 271–8.
27. Mahajan R, Xing J, Liu SJ et al. Mortality among persons in care with hepatitis C virus infection: the chronic hepatitis cohort study (CHeCS), 2006-2010. Clin. Infect. Dis. 2014; 58: 1055–61.
28. Yang M, Wu E, Fu S et al. Prevalence of hepatitis B core antibody (anti-HBc) and association with hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection in the United States (US) and China. Hepatology 2015; 62: Abstract 1850.